4D Molecular Therapeutics (FDMT) said Friday that it will focus on two product candidates: 4D-150 for wet AMD and DME, and 4D-710 for cystic fibrosis.
The company said the two candidates have the strongest clinical proof of concept within its product pipeline.
4D said it is on track to begin late-stage trials for wet AMD in Q1 and Q3 respectively, with primary endpoint 52-week topline data expected in H2 2027.
Shares of the biotech firm were up 5.7% in recent premarket activity.
Price: 6.16, Change: +0.32, Percent Change: +5.65
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。